Drug-eluting stents as opposed to bare metal stents should be used in below-the-knee lesions, if stenting is unavoidable, suggest one-year results of the PES-BTK-70 study, which is investigating the below-the-knee arterial use of self-expanding paclitaxel-coated stents.
The first commercial implant of the AFX2 bifurcated endograft system (Endologix) in the USA has been performed at Main Medical Center in Portland. The implantation was performed by Paul Bloch, associate professor at Tufts University School of Medicine, and vascular surgeon at Main Medical Center.
Acute mesenteric ischaemia (AMI) can be successfully treated with endovascular therapy such as balloon angioplasty, according to research from the University of Eastern Finland. The study also found that AMI is a more common cause of abdominal pain among the elderly than generally thought; however, it is difficult to diagnose before bowel damage develops.
Lombard Medical has announced that the first commercial procedure in Germany using the Altura endovascular stent graft was successfully completed at the Saarland University Medical Center-Clinic for Diagnostic and Interventional Radiology, Saarland, Germany. The procedure follows the late January Leipzig Interventional Course (LINC) in Leipzig, Germany.
The US Food and Drug Administration (FDA) has confirmed the appointment of Robert Califf as its 22nd commissioner, following a US Senate vote of 88 to 4 in his favour.
ReCor Medical has been granted US Food and Drug Administration investigational device exemption approval for the RADIANCE-HTN clinical trial. This trial will measure the effect of ReCor’s Paradise renal denervation system on blood pressure, in patients with hypertension.
Boston Scientific has received CE mark for the Eluvia drug-eluting vascular stent. It is to begin commercialisation of the product immediately in countries which recognise CE mark.
Long-term follow-up results of the CREST trial show no significant difference between patients who underwent stenting and those who underwent endarterectomy with respect to the risk of periprocedural stroke, myocardial infarction, or death and subsequent ipsilateral stroke at 10 years. The rate of postprocedural ipsilateral stroke also did not differ between groups.
Nipro North America, a division of Nipro Medical Corporation, has launched the Cronus HP high-pressure, 0.035” over-the-wire percutaneous transluminal angioplasty balloon catheter.
A clinical trial has found no significant differences between the use of carotid-artery stenting and carotid endarterectomy over a period of five years for the prevention of strokes in asymptomatic patients with serious narrowing of the carotid artery.
The first two patients in the European Peregrine system post-market study have been treated by Wojtek Wojakowski and Mariusz Hochul in Poland, Ablative Solutions has announced.
More than 250,000 patients have been treated with the Gore Excluder abdominal aortic aneurysm (AAA) endoprosthesis, the company has announced. This marks a significant milestone for the device, which received CE mark in 1997, and US Food and Drug Administration (FDA) approval in 2002.
A 12-month update on a study investigating the use of the Absorb drug-eluting scaffold (Abbott) in below-the-knee arteries (ABSORB BTK) indicates that bioresorbable vascular stents can achieve good immediate angiographic results and promising 12-month patency.
Peripheral artery disease patients who undergo endovascular treatment may have a lower risk of major and life-threatening bleeding events and a lower risk or restenosis or occlusion when treated with edoxaban and aspirin, rather than with clopidogrel and aspirin, according to a new proof of concept study.
Two cases have been successfully completed using the AorFit (Aortica) system to support simplified fenestrated endovascular aneurysm repair (FEVAR). The surgeries were performed by Benjamin Starnes, chief of Vascular Surgery, University of Washington, USA, as part of his physician-sponsored investigational device exemption study.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos